A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream
NCT06213831
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
23
Enrollment
INDUSTRY
Sponsor class
Conditions
Prurigo Nodularis
Interventions
DRUG:
Ruxolitinib Cream 1.5%
Sponsor
Incyte Corporation